|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07D 487/04 | |
| A61K 31/4375 | |||
| A61P 25/16 | |||
| A61P 25/22 | |||
| A61P 25/24 | |||
| A61P 25/28 |
| (11) | Number of the document | 2970290 |
| (13) | Kind of document | T |
| (96) | European patent application number | 13878220.6 |
| Date of filing the European patent application | 2013-05-14 | |
| (97) | Date of publication of the European application | 2016-01-20 |
| (45) | Date of publication and mention of the grant of the patent | 2020-07-22 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/AU2013/000497 |
| Date | 2013-05-14 |
| (87) | Number | WO 2014/138772 |
| Date | 2014-09-18 |
| (30) | Number | Date | Country code |
| 201361787436 P | 2013-03-15 | US | |
| 2013204159 | 2013-04-12 | AU |
| (72) |
FLYNN, Bernard Luke, AU
PAUL, Dharam, AU
HARVEY, Andrew John, AU
|
| (73) |
Bionomics Limited,
31 Dalgleish Street, Thebarton, South Australia 5031,
AU
|
| (54) | A CRYSTALLINE FORM OF AN ANXIOLYTIC COMPOUND |
| A CRYSTALLINE FORM OF AN ANXIOLYTIC COMPOUND |